Follow RSS for latest reports on this topicUlcerative Colitis - Market Research and Reports

Ulcerative colitis is a disease that affects around 120,000 people in the UK and causes inflammation of the large intestine - or colon. Symptoms vary in severity from pain and discomfort, through mucous in the stools to in the most severe cases blood in the stools. It is generally diagnosed by inspection of the colon by a hospital consultant - a colonoscopy.

The underlying cause of ulcerative colitis is still not known - though the disease is associated with dysfunction of the immune system. In the disease the body's own T-cells attack the lining of the bowel - and hence cause it to be inflamed. This bodies immune system then takes this inflammation to be a further sign of infection - increasing the immune response - in a vicious cycle. This situation is what people would term a flare-up.

Ulcerative colitis is treated using a variety of medications designed to either directly reduce the inflammation - such as steroids - or to reduce the immune response such a immunomodulators. Standard treatment for ulcerative colitis depends on extent of involvement and disease severity. The goal is to induce remission initially with medications, followed by the administration of maintenance medications to prevent a relapse of the disease. The concept of induction of remission and maintenance of remission is very important. The medications used to induce and maintain a remission somewhat overlap, but the treatments are different. Physicians first direct treatment to inducing a remission which involves relief of symptoms and mucosal healing of the lining of the colon and then longer term treatment to maintain the remission.The medications include; Asacol / Mesalazine / Colazine, Steroids, Azathioprine/immuno-modulators, Remicade and Laxatives.


BioPortfolio's Easy Ordering System

  1. Search for the report you need from our store
  2. Make online payment with our easy checkout process
  3. Receive PDF report via email

Easy Online Payment or Pro Forma Invoice

We accept the following credit cards...

or can supply a pro-forma invoice if required.

Related Reports:

We found over 40 reports that matched your search.

Next 40 Matches >

Refine your search, and find more matches, using the form above.

Inflammatory Bowel Disease (IBD) Treatment Market, By Type (Crohn’s Disease, and Ulcerative Colitis), By Route of Administration (Oral, and Injectable), By Distribution Channel (Online Pharmacy, Retail Pharmacy, and Hospital Pharmacy), and By Geography (NA, EU, APAC, LATAM and MEA) – Analysis, Share, Trends, Size, & Forecast from 2020 – 2026- COVID-19 Updated

REPORT HIGHLIGHTInflammatory Bowel Disease (IBD) Treatment market was valued at USD 15.87 billion by 2019, growing with 4.1% CAGR during the forecast period, 2020-2026Market DynamicsA rise in the number of drugs available in clinical tests, growing prevalence of inflammatory bowel disease (IBD), and rising government initiatives related to the analysis of the causes and effective novel drug develo...Read More >>>


Published by: AnalystView

Prices Starting From:

save $488 today

Ulcerative Colitis Market by Molecule Type (Biologics and Small Molecules), by Disease Type (Mild Ulcerative Colitis, Moderate Ulcerative Colitis, Severe Ulcerative Colitis), by Route of Administration (Oral and Injectables) - Global Opportunity Analysis and Industry Forecast, 2017-2023

Ulcerative colitis (UC) is an inflammatory gastrointestinal disease that affects colon or large intestine. UC is characterized as an incurable disease with low mortality rate and is generally diagnosed in adolescence and early adulthood. As per NCBI, about 1.86 billion patients were diagnosed with UC globally in 2014, with 1.54 billion patients currently receiving treatment. Moreover, it is estima...Read More >>>


Published by: Allied Market Research

Prices Starting From:

save $516 today

Additional Searches

You may also like to search separately for: Ulcerative Colitis

We Stock...